Dual mTORC1/2 and HER2 blockade results in antitumor activity in preclinical models of breast cancer resistant to anti-HER2 therapy. - Wikidata - wikimedia - TriplyDB

Dual mTORC1/2 and HER2 blockade results in antitumor activity in preclinical models of breast cancer resistant to anti-HER2 therapy.

Dual mTORC1/2 and HER2 blockade results in antitumor activity in preclinical models of breast cancer resistant to anti-HER2 therapy.

http://www.wikidata.org/entity/Q39381586

about

PI3K/Akt/mTOR inhibitors in breast cancer Patient-derived xenograft models of breast cancer and their predictive power mTOR kinase inhibitors as potential cancer therapeutic drugs Dual phosphoinositide 3-kinase/mammalian target of rapamycin inhibitor NVP-BEZ235 has a therapeutic potential and sensitizes cisplatin in nasopharyngeal carcinoma From bench to bedside: What do we know about hormone receptor-positive and human epidermal growth factor receptor 2-positive breast cancer?Resistance to mTOR kinase inhibitors in lymphoma cells lacking 4EBP1 Pten loss promotes MAPK pathway dependency in HER2/neu breast carcinomas PI3K and cancer: lessons, challenges and opportunities Epidermal growth factor-receptor activation modulates Src-dependent resistance to lapatinib in breast cancer models.Generation of a patient-derived chordoma xenograft and characterization of the phosphoproteome in a recurrent chordoma.TAK-228 (formerly MLN0128), an investigational dual TORC1/2 inhibitor plus paclitaxel, with/without trastuzumab, in patients with advanced solid malignancies.The mTOR inhibitor rapamycin synergizes with a fatty acid synthase inhibitor to induce cytotoxicity in ER/HER2-positive breast cancer cells Identification of mTORC2 as a necessary component of HRG/ErbB2-dependent cellular transformation Epstein-Barr virus-encoded latent membrane protein 2A promotes the epithelial-mesenchymal transition in nasopharyngeal carcinoma via metastatic tumor antigen 1 and mechanistic target of rapamycin signaling induction.Tailoring mTOR-based therapy: molecular evidence and clinical challenges.Current status of anti-human epidermal growth factor receptor 2 therapies: predicting and overcoming herceptin resistance MTDH mediates trastuzumab resistance in HER2 positive breast cancer by decreasing PTEN expression through an NFκB-dependent pathway Antagonism of EGFR and HER3 enhances the response to inhibitors of the PI3K-Akt pathway in triple-negative breast cancer.MYC-xing it up with PIK3CA mutation and resistance to PI3K inhibitors: summit of two giants in breast cancers MLN0128, an ATP-competitive mTOR kinase inhibitor with potent in vitro and in vivo antitumor activity, as potential therapy for bone and soft-tissue sarcoma.mTOR kinase inhibitors synergize with histone deacetylase inhibitors to kill B-cell acute lymphoblastic leukemia cells.SDF-1/CXCL12 induces directional cell migration and spontaneous metastasis via a CXCR4/Gαi/mTORC1 axis.PI3K inhibition results in enhanced estrogen receptor function and dependence in hormone receptor-positive breast cancer.Combining AZD8931, a novel EGFR/HER2/HER3 signalling inhibitor, with AZD5363 limits AKT inhibitor induced feedback and enhances antitumour efficacy in HER2-amplified breast cancer models.Improving gastric cancer preclinical studies using diverse in vitro and in vivo model systems.The combination of an mTORc1/TORc2 inhibitor with lapatinib is synergistic in bladder cancer in vitro.The Therapeutic Challenge of Targeting HER2 in Endometrial Cancer The preclinical evaluation of the dual mTORC1/2 inhibitor INK-128 as a potential anti-colorectal cancer agent.Dual HER2/PIK3CA Targeting Overcomes Single-Agent Acquired Resistance in HER2-Amplified Uterine Serous Carcinoma Cell Lines In Vitro and In Vivo.Preclinical Efficacy of Ron Kinase Inhibitors Alone and in Combination with PI3K Inhibitors for Treatment of sfRon-Expressing Breast Cancer Patient-Derived Xenografts.NRF2 Regulates HER2 and HER3 Signaling Pathway to Modulate Sensitivity to Targeted Immunotherapies.Overcoming resistance and restoring sensitivity to HER2-targeted therapies in breast cancer.Alterations in cellular metabolome after pharmacological inhibition of Notch in glioblastoma cells.Efficacy of the investigational mTOR kinase inhibitor MLN0128/INK128 in models of B-cell acute lymphoblastic leukemia.Activating Mutations in ERBB2 and Their Impact on Diagnostics and Treatment.Dual mTOR inhibitor MLN0128 suppresses Merkel cell carcinoma (MCC) xenograft tumor growth.Anthricin Isolated from Anthriscus sylvestris (L.) Hoffm. Inhibits the Growth of Breast Cancer Cells by Inhibiting Akt/mTOR Signaling, and Its Apoptotic Effects Are Enhanced by Autophagy Inhibition.Rationale-based therapeutic combinations with PI3K inhibitors in cancer treatment PI3K inhibition impairs BRCA1/2 expression and sensitizes BRCA-proficient triple-negative breast cancer to PARP inhibition.mTORC1 inhibition is required for sensitivity to PI3K p110α inhibitors in PIK3CA-mutant breast cancer.

P2860

Q26771394-8B17CB97-A2F0-4F3E-BFD2-679C6050D4B0 Q27026531-57A8F539-568E-4A59-A589-9EB7D54A1340 Q27027963-95637B1B-3F88-4FB4-8B2E-CC3C1EC1B1B2 Q27332333-1676D9D0-12B1-47B3-8B09-D38476B031C4 Q28084982-16A6C038-1E63-46B3-A756-B2ED31E73CA3 Q28540038-ACBEF4D6-C742-40D4-8D64-C7F5B000C0D7 Q28602310-93EDDE7A-CAF5-470E-B7E4-ADEEF6B96C47 Q30080017-B41B449B-DC04-4486-99BD-5CA5EFF321A3 Q30412086-7C90C087-782D-4782-B8C8-5A77A8E17B7C Q33275031-1EB86D97-399F-487A-9976-0FF3F2420350 Q33442621-5CB613D7-2B88-4BC8-BCE8-409987476D67 Q33670472-875FEDF8-72FC-4907-B723-39E89F2BA50B Q33758255-9B615F27-5C9D-4E4D-A5F3-6D1DAF00436C Q34261571-70521A52-6E39-47CD-9F57-00FF4A0F6183 Q34294170-525451AE-FC16-430A-88BF-A34700E5E077 Q34355748-1D3CA54B-753E-436B-AFD3-36479DE63C96 Q34622404-9AE6B86E-700F-405C-BA41-C2B01D35CB86 Q34813272-921BA521-726C-4FC2-9395-E3300DF1CED0 Q34991267-8565011C-F8E8-4707-9AE4-E8A47385ED42 Q35096201-C53DB247-ADD9-4AB4-810C-F2EE19A2D01D Q35273390-3BDDCA40-6609-4BC7-A48A-3168550669C5 Q35576488-F1352FD8-F4B3-4E73-86BA-6B6D39339E5E Q35610581-8BBBDC69-1C98-425A-AFFE-7EB117AB8834 Q35849919-F7DBD0EB-312D-40BE-8278-5D167476BE28 Q35949785-59C4D4F4-C0EF-430E-A3F6-2500B4FF9700 Q36027204-85FC07E8-AB55-44BF-8F82-322E11185B36 Q36064912-6E286BAA-4C28-41F5-8420-825CE769CB72 Q36215450-1CB46898-EBB3-4FE1-AA78-906DEBBB7C37 Q36258125-EE9AB5CF-2C82-47CD-9476-C2E1D4B9651F Q36377994-1300A163-99D9-4AD0-BA99-C0EDB3F3DDD2 Q36387554-2FCDF544-1CC2-4B13-89C0-1A6479C408A9 Q36408570-B8D8FD2F-ABDB-4DFE-8022-8D739D42BDFF Q36633528-076CFCCD-8105-4A4C-BFBD-FD4150AFEC2C Q36673421-F0CA452B-E36C-4C67-889C-C96C0150530B Q36785721-30A883A7-351C-48D6-AAA9-68CD33D13D90 Q36916277-956FB3AB-BA4C-4B0D-A3E7-2DBBC514B6CD Q36925611-6E2BB9A0-2834-4888-9FAA-AB3A784552C8 Q36997524-5898B4D7-CBE5-4474-8983-3A85BB3E03DB Q37445131-706D45CC-28FA-4971-B55F-4187D5B61FF5 Q37605004-DA51E837-44FF-43DB-86BB-176914D46C8D

P2860

Dual mTORC1/2 and HER2 blockade results in antitumor activity in preclinical models of breast cancer resistant to anti-HER2 therapy.

http://www.wikidata.org/entity/Q39381586

description

2012 nî lūn-bûn

@nan

2012年の論文

@ja

2012年学术文章

@wuu

2012年学术文章

@zh-cn

2012年学术文章

@zh-hans

2012年学术文章

@zh-my

2012年学术文章

@zh-sg

2012年學術文章

@yue

2012年學術文章

@zh

2012年學術文章

@zh-hant

name

Dual mTORC1/2 and HER2 blockad ...... esistant to anti-HER2 therapy.

@en

Dual mTORC1/2 and HER2 blockad ...... esistant to anti-HER2 therapy.

@nl

type

label

Dual mTORC1/2 and HER2 blockad ...... esistant to anti-HER2 therapy.

@en

Dual mTORC1/2 and HER2 blockad ...... esistant to anti-HER2 therapy.

@nl

prefLabel

Dual mTORC1/2 and HER2 blockad ...... esistant to anti-HER2 therapy.

@en

Dual mTORC1/2 and HER2 blockad ...... esistant to anti-HER2 therapy.

@nl

P1433

Q39381586-6D03D7E3-AAD9-44F3-A84C-4D22C7DB8F3D

P1476

Q39381586-DC4B4848-BA78-404B-B1EA-7656DB73B171

P2093

Q39381586-027A8477-981A-4C98-8286-2DDF54369AFC

Q39381586-0CCD12CC-6462-4577-9A9D-67A6B237FF43

Q39381586-18D56B60-1651-437B-957F-36BB464FADCD

Q39381586-253DF359-F39D-46EC-924C-351DB2980AF8

Q39381586-62698278-CC41-4F42-8D46-B0301BF62BCB

Q39381586-81807A15-4036-4C5E-B72D-AB76925CF418

Q39381586-8A10810F-523B-4821-A979-87CC03D56947

Q39381586-8F76D7F8-C562-47CF-9E20-77D0CCEC2E22

Q39381586-9E73A2E1-CEA2-4E7A-8CD5-FD34EC1CA103

Q39381586-A341094F-E124-41A0-AF1A-8F90AEA8BE59

P304

Q39381586-DAB2FCF6-4C0F-42BB-B21C-D9D75838CC85

P31

Q39381586-0B041536-3645-4415-91B2-B1E12850CA9C

P356

Q39381586-DD3751D3-1E98-443A-BCB0-F89462B03A56

P407

Q39381586-9E9AADFD-A64F-4BCC-8F97-3028D3857666

P433

Q39381586-94ABBAE8-2AB3-42AF-B4D9-A48F3E9D934F

P478

Q39381586-BC11375F-A65A-48EB-AB88-17730E6871B0

P50

Q39381586-60D07229-C3BB-4C1B-8D00-8C40CAAC06CF

Q39381586-B4BB30AB-578C-4AC9-ADEB-001D67741225

P577

Q39381586-68900F03-41FC-49B5-970A-F3D6B7699B01

P698

Q39381586-78432D39-2F4E-41E9-8D21-7FC17B984DD7

P356

1078-0432.CCR-11-2750

P1433

Clinical Cancer Research

P1476

Dual mTORC1/2 and HER2 blockad ...... esistant to anti-HER2 therapy.

@en

P2093

Celina García-García

http://www.w3.org/2001/XMLSchema#string

Christian Rommel

http://www.w3.org/2001/XMLSchema#string

Claudia Aura

http://www.w3.org/2001/XMLSchema#string

José Baselga

http://www.w3.org/2001/XMLSchema#string

José Pérez

http://www.w3.org/2001/XMLSchema#string

Judit Grueso

http://www.w3.org/2001/XMLSchema#string

Katti Jessen

http://www.w3.org/2001/XMLSchema#string

Maria Teresa Calvo

http://www.w3.org/2001/XMLSchema#string

Marta Guzmán

http://www.w3.org/2001/XMLSchema#string

Maurizio Scaltriti

http://www.w3.org/2001/XMLSchema#string

P304

2603-2612

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1158/1078-0432.CCR-11-2750

http://www.w3.org/2001/XMLSchema#string

P407

P433

9

http://www.w3.org/2001/XMLSchema#string

P478

18

http://www.w3.org/2001/XMLSchema#string

P50

Josep Tabernero

P577

2012-03-08T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

22407832

http://www.w3.org/2001/XMLSchema#string